Aclaris Therapeutics (ACRS) Form 3 Aclaris Therapeutics / Joseph Monahan ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Monahan Joseph

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

640 LEE ROAD, SUITE 200

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/05/2021

3. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	57,132	D
Common Stock	193	I	By Spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	08/31/2027	Common Stock	56,000	25.8	D
Employee Stock Option (Right to Buy)	(2)	01/31/2028	Common Stock	14,700	22.09	D
Restricted Stock Units	(3)	(3)	Common Stock	2,333	(4)	D
Restricted Stock Units	(5)	(5)	Common Stock	1,050	(4)	D
Restricted Stock Units	(6)	(6)	Common Stock	27,500	(4)	D
Restricted Stock Units	(7)	(7)	Common Stock	50,000	(4)	D
Restricted Stock Units	(8)	(8)	Common Stock	37,500	(4)	D
Restricted Stock Units	(9)	(9)	Common Stock	200,000	(4)	D

Explanation of Responses:

1. The option vests over a period of four years. 75% of the shares are currently vested with the remaining 25% vesting on September 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.

2. The option vests over a period of four years. 75% of the shares are currently vested with the remaining 25% vesting on February 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.

3. The shares underlying these restricted stock units vest on September 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

4. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

5. The shares underlying these restricted stock units vest on February 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

6. The shares underlying these restricted stock units vest over a period of two years, with 50% vesting on March 1, 2022 and 50% vesting on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

7. The shares underlying these restricted stock units vest on June 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

8. The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 2, 2022, March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

9. The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on March 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Mark Ballantyne, as Attorney-in-Fact	05/17/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.